Tokyo-based Eisai Co announced it will cut about 25 percent --450 jobs -- in the U.S. as part of a realignment effort to increase efficiency.
Eisai has U.S. locations in New Jersey, North Carolina, Massachusetts, Pennsylvania and Maryland. The layoffs, according to FierceBiotech, will be made before the end of April and will eliminate "various" parts of the company's 1,800 U.S. workers.
Eisai, which began with a two-brand structure built on anti-Alzheimer's drug Aricept and acid reflux treatment Pariet, expanded its portfolio to launch oncology, epilepsy and obesity treatments, including well-know drugs such as Humira, Lyrica and Belviq.
Read the Reuters press release